Building a Succinate Accumulation Model

Succinate accumulates in the matrix; reaching the enzymes is a separate claim.

Three Ways to Raise Succinate

ApproachMechanismSpeedCaveat
SDH inhibition (malonate, TTFA, 3-NPA)Competitive or irreversible inhibition of complex IIMinutes to hoursOff-target effects; competitive with succinate
SDH subunit knockout (SDHA–D)Loss of complex IIWeeksLethality in some lines; adaptation
FH lossFumarate accumulates and back-fluxes to succinateWeeksBoth metabolites rise; effects overlap
Ischaemia or reoxygenation modelsReverse SDH flux during ischaemiaMinutesTransient; difficult to control

Important distinction. SDH inhibition raises succinate by blocking its oxidation; FH loss raises succinate indirectly by mass action through reversible fumarase. The two produce different accompanying metabolite changes — fumarate is high in both, but the ratio differs — and the downstream effects are not identical.

Part 1 — The Compartment Problem

CompartmentWhat accumulatesHow to measure
Mitochondrial matrixMillimolar succinate in SDH-deficient modelsMitochondrial isolation; or inferred from downstream effects
CytosolLower and less certainFractionation; metabolite biosensors
ExtracellularExported; measurable in mediumMedium LC-MS

Caveat on whole-cell values. A whole-cell succinate measurement is dominated by the mitochondrial pool, which is thousands of times larger in volume-normalised terms than the cytosolic pool in some cells. A rise in the whole-cell value can occur with little change in the cytosolic concentration that would reach a nuclear dioxygenase.

Readout note. The practical consequence is that a succinate claim should be paired with a downstream readout that reports the effect rather than the concentration — PHD activity via HIF, or a demethylase effect via a methylation mark — because those integrate concentration and compartment into a functional endpoint.

Part 2 — Inhibitor Choices

AgentTargetReversibilityNote
MalonateComplex II, competitive with succinateReversibleRequires high concentrations; competes with the substrate
TTFAComplex II, Q-siteReversibleWeak; high concentrations needed
3-NitropropionateComplex II, irreversibleIrreversibleRecovery requires new enzyme
Dimethyl malonateCell-permeable prodrugReversibleUsed in vivo; esterase-dependent

Caveat on malonate. Because malonate competes with succinate at the same site, raising succinate concentration partially overcomes the inhibition. In a model where succinate accumulates, the inhibitor's effective potency falls — which can produce a plateau that looks like a saturable biological effect.

Part 3 — Building the Genetic Model

StepRequirementNote
TargetSDHB (soluble, stable) is often chosen for complete lossSDHA loss can be tolerated in some lines
EditingTwo independent guides; or inducibleLethality requires inducibility
SelectionGrowth in uridine-free or specific conditions if neededComplex II loss does not require uridine
VerificationSubunit immunoblot; complex II activity; succinate measurementThree levels
PhenotypeHIF or methylation readoutConcentration alone is insufficient
ComparatorIsogenic wild-type at matched passageAdaptation confound

Readout note. Complex II is entirely nuclear-encoded, so SDH knockouts are straightforward genetically; but the metabolic consequences include accumulation of both succinate and, in some settings, ROS from the altered Q pool. A phenotype in an SDH knockout is therefore not exclusively a succinate phenotype.

Part 4 — What the Model Supports

ClaimRequiresNot sufficient
"Succinate accumulated"Quantified succinate, with compartment inferenceA fold-change in whole cells
"PHD was inhibited"HIF stabilisation with a PHD-dependent readout, or PHD activityHIF protein alone
"DNA methylation changed"5mC/5hmC measurement with a demethylase-dependent designA single locus
"Succinate mediates the phenotype"Succinate-lowering rescue, or comparison with an SDH-independent succinate sourceCorrelation
"The model recapitulates SDH-deficient tumours"Genotype plus metabolite plus phenotype concordanceAny one of the three

Part 5 — Common Failures

  • • Whole-cell succinate used to infer nuclear enzyme inhibition.
  • • Malonate described as a specific SDH inhibitor without noting substrate competition.
  • • FH loss used as a "succinate model", when fumarate is the distinguishing metabolite.
  • • HIF stabilisation attributed to succinate without excluding other PHD inhibitors in the model.
  • • Knockout verified by genotype only.
  • • No isogenic comparator, so adaptation is confounded with genotype.
  • • Succinate measured at a single timepoint, before the pool has equilibrated.
  • • Inhibitor concentrations taken from the literature without a dose–response.

Part 6 — Where This Article Connects

This is the model-building article of the mitochondrial cluster, paired with the oncometabolite article that covers the dioxygenase logic. It connects to the 2-HG detection article, where the enantiomer problem is analogous, and to the respiratory chain article, where complex II's nuclear encoding is discussed.

If you need succinate models with compartment inference and downstream functional readouts, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Succinate accumulation, compartment distribution and downstream effects vary with the lesion, cell type and time after perturbation. The models here are described at the level of principle.

An increased succinate concentration does not establish inhibition of a specific dioxygenase, and a phenotype in an SDH-deficient model is not exclusively a succinate phenotype.

Scientific interpretation and experimental design

  • • Compartment is the issue. Whole-cell values are dominated by mitochondria.
  • • Add a functional readout. HIF or methylation.
  • • Malonate competes with succinate. Potency falls as succinate rises.
  • • FH loss is not an SDH model.
  • • Verify at three levels.
  • • Isogenic comparator, matched passage.

Selected references for further reading

  • • Selak MA, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7:77–85.
  • • Xiao M, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate. Genes & Development. 2012;26:1326–1338.
  • • Chouchani ET, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–435.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: